Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma

Sharon M. Castellino; Qinglin Pei; Susan K. Parsons; David Hodgson; Kathleen M. McCarten; Terzah M. Horton; Steve Cho; Yue Wu; Angela Punnett; Hema Dave; Tara O. Henderson; Bradford S. Hoppe; Anne-Marie Charpentier; Frank G. Keller; Kara M. Kelly

doi:10.1056/nejmoa2206660

November 2, 2022New England Journal of MedicineOpen Access

Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma

View Full Paper

Ask AI

Bookmark

Share

Key Points

To assess the efficacy and safety of adding brentuximab vedotin to standard chemotherapy in pediatric patients with high-risk Hodgkin's lymphoma.
Interventional randomized trial (AHOD1331, ClinicalTrials.gov number NCT02166463) evaluating the addition of brentuximab vedotin to standard chemotherapy in pediatric high-risk Hodgkin's lymphoma.
Outcomes were tracked through 3 years of follow-up to evaluate disease events, mortality, and the incidence of toxic effects.
The addition of brentuximab vedotin to standard chemotherapy resulted in superior efficacy, demonstrating a 59% lower risk of an event or death at 3 years.
No increase in the incidence of toxic effects was observed at 3 years with the addition of brentuximab vedotin.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Demonstrates superior efficacy and reduced event risk in pediatric high-risk Hodgkin lymphoma, highlighting improved survival without added toxicity.

Abstract

The addition of brentuximab vedotin to standard chemotherapy resulted in superior efficacy, with a 59% lower risk of an event or death, and no increase in the incidence of toxic effects at 3 years. (Funded by the National Institutes of Health and others; AHOD1331 ClinicalTrials.gov number, NCT02166463.).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Castellino et al. (2022) studied this question.

synapsesocial.com/papers/69d763a35f9a1dad53490052 https://doi.org/10.1056/nejmoa2206660

View Full Paper

Ask AI

Bookmark

Share

Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading